Covers composition of mat­ter and method of use for pro­pri­e­tary PDCs™ in com­bi­na­tion with anti-cancer agents

Madison, WI (Press Release) – Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the discovery, de­vel­op­ment and com­mer­cial­i­za­tion of targeted treat­ments for cancer, an­nounces that the U.S. Patent and Trademark Office (USPTO) has granted pat­ent num­ber 9,345,718, titled “Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles,” re­lated to the com­pany’s phos­pho­lipid-ether analogs for targeting anticancer thera­peutics to tumors and cancer stem cells.

“This seminal pat­ent provides Cellectar with broad pro­tec­tion for Phospholipid Drug Conjugate™ (PDC™) prod­ucts created with our phos­pho­lipid ether tech­nology, as well as the freedom to op­er­ate that is nec­es­sary to …

Madison, WI (Press Release) – Cellectar Biosciences, Inc. (Nasdaq:CLRB), an on­col­ogy-focused, clin­i­cal stage bio­technology com­pany (the "company"), to­day an­nounces its lead PDC com­­pound, CLR 131 has achieved a median over­all sur­vival of 22.5 months to date after a single dose in­fusion of 12.5mCi/m² in patients with mul­ti­ple myeloma. Patients in the first cohort of the com­pany's Phase 1 clin­i­cal trial had an average of 5.8 prior lines of treat­ment and there­fore were con­sidered to be heavily pre­treated.

It is im­por­tant to note that the trial remains on­go­ing, and the over­all sur­vival could con­tinue …

Safety and Activity Data Reviewed From First Cohort of Patients; CLR 131 Performance Triggers Advancement Into Second Cohort at Higher Dose

Madison, WI (Press Release) – Cellectar Biosciences, Inc. (NASDAQ:CLRB), an on­col­ogy-focused bio­tech­nology com­pany, to­day an­nounces data from the first cohort of patients en­rolled in its orphan drug-desig­nated Phase 1 study of CLR 131 in patients with re­lapsed or re­frac­tory mul­ti­ple myeloma. Based on safety and ef­fi­cacy data from the first cohort, the trial’s Data Monitoring Com­mit­tee approved en­roll­ment of the sec­ond cohort of patients with a 50 per­cent escalation in dose level of CLR 131.

The pri­mary objective of the multi-center, open label, Phase 1 dose escalation study is to char­ac­ter­ize …

Madison, WI (Press Release) – Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clin­i­cal stage bio­phar­ma­ceu­tical com­pany devel­op­ing inno­va­tive agents for the detection and treat­ment of cancer, an­nounced the ini­ti­a­tion of patient dosing in a proof-of-concept trial of I-131-CLR1404 in patients with re­lapsed or re­frac­tory mul­tiple myeloma, an indi­ca­tion for which I-131-CLR1404 pre­vi­ously re­ceived orphan drug desig­na­tion from the U.S. Food and Drug Admin­istra­tion.

Multiple myeloma is an incurable malig­nan­cy for which novel ther­a­pies are needed. The radiosensitivity of mul­ti­ple myeloma is well doc­u­mented. I-131-CLR1404 is de­signed to allow for targeted de­livery of ionizing radi­a­tion …

Madison, WI (Press Release) - Cellectar Biosciences, Inc. (Nasdaq:CLRB), an­nounced to­day that the U.S. Food & Drug Admin­istra­tion (FDA) has ac­cepted the Com­pany's inves­ti­ga­tional new drug (IND) appli­ca­tion to begin clin­i­cal study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with re­lapsed or re­frac­tory mul­ti­ple myeloma, an incurable cancer of plasma cells.

I-131-CLR1404 is radiotherapeutic com­prised of a pro­pri­e­tary phos­pho­lipid ether (PLE) analog, acting as a cancer-targeted de­livery and retention vehicle, covalently labeled with Iodine-131, a cytotoxic radioisotope that is already commonly used to treat thyroid and other cancer types. Because Cellectar's …

Madison, Wisconsin (Press Release) - Cellectar Biosciences, Inc. (OTCQX:CLRB), an­nounced that it has sub­mitted an Inves­ti­ga­tional New Drug (IND) appli­ca­tion to the U.S. Food & Drug Admin­istra­tion (FDA) to begin clin­i­cal study of I-131-CLR1404, a highly-selective, cancer-targeting radio­phar­ma­ceut­i­cal, in patients with re­lapsed / re­frac­tory mul­ti­ple myeloma, an incurable cancer of plasma cells.

"Despite the emergence of new treat­ment op­tions, no cure exists for mul­ti­ple myeloma and the lim­i­ta­tions of avail­able ther­a­pies are par­tic­u­larly evident in patients that have re­lapsed or be­come resistant to treat­ment creating a clear need for the devel­op­ment of addi­tional …